相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma
N. Shinohara et al.
ANNALS OF ONCOLOGY (2014)
Sorafenib Use in Hepatocellular Carcinoma: More Questions Than Answers
Ghassan K. Abou-Alfa
HEPATOLOGY (2014)
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma
Koji Miyahara et al.
HEPATOLOGY RESEARCH (2014)
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
R. Lencioni et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Sorafenib in Advanced Hepatocellular Carcinoma Hypertension as a Potential Surrogate Marker for Efficacy
Bassam Estfan et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani et al.
ANNALS OF ONCOLOGY (2013)
Sorafenib: from literature to clinical practice
V. Di Marco et al.
ANNALS OF ONCOLOGY (2013)
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival
Alexandra Shingina et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2013)
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma
Luigi Bolondi et al.
DIGESTIVE AND LIVER DISEASE (2013)
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective
Massimo Colombo et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
Takahide Nakazawa et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Giuseppe Cabibbo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit
Salvatore D'Angelo et al.
FUTURE ONCOLOGY (2013)
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
Calogero Camma et al.
HEPATOLOGY (2013)
Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design
Maria Reig et al.
HEPATOLOGY (2013)
Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma
Giovan Giuseppe Di Costanzo et al.
MEDICAL ONCOLOGY (2013)
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Lorenza Rimassa et al.
ONCOLOGIST (2013)
Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series
Liliana Montella et al.
ONCOLOGY (2013)
Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma
Naoshi Nishida et al.
ONCOLOGY (2013)
Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations
A. Ruth He et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Verslype et al.
ANNALS OF ONCOLOGY (2012)
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
Julien Edeline et al.
CANCER (2012)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Early detection, prevention and management Of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group
Sergio Bracarda et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
Giovan Giuseppe Di Costanzo et al.
DIGESTIVE AND LIVER DISEASE (2012)
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
Kim Edmonds et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2012)
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience
Giuseppa Scandurra et al.
FUTURE ONCOLOGY (2012)
Cyclic AMP/PKA-dependent Paradoxical Activation of Raf/MEK/ERK Signaling in Polycystin-2 Defective Mice Treated With Sorafenib
Carlo Spirli et al.
HEPATOLOGY (2012)
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
Nicola Personeni et al.
JOURNAL OF HEPATOLOGY (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Evaluation of the mRECIST and alpha-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
Tomokazu Kawaoka et al.
ONCOLOGY (2012)
Treatment of Hepatocellular Carcinoma with Sorafenib - Focus on Special Populations and Adverse Event Management
E. Schott et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2012)
Cancer-related fatigue: a practical review
M. P. O. Campos et al.
ANNALS OF ONCOLOGY (2011)
Experience with sorafenib and adverse event management
Joaquim Bellmunt et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
Giuseppe Cabibbo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy
Massimo Iavarone et al.
HEPATOLOGY (2011)
The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)
Hilda Wong et al.
ONCOLOGIST (2011)
Early Decrease in alpha-Fetoprotein, but Not Des-gamma-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2011)
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib
Giovanni Abbadessa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients With Advanced Hepatocellular Carcinoma
Yu-Yun Shao et al.
CANCER (2010)
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
Markus Peck-Radosavljevic et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma
Giuseppe Cabibbo et al.
HEPATOLOGY (2010)
Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
R. Lencioni et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
Bruno Vincenzi et al.
ONCOLOGIST (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
Antonius A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
